PMA P890064S009

Device
DIGENE HYBRID CAPTURE 2 (HC2) HIGH-RISK HPV DNA TEST
Applicant
Qiagen Gaithersburg, Inc.
PMA number
P890064
Supplement
S009
Product code
MAQ
Decision date
2003-03-31
Classification
Kit, Dna Detection, Human Papillomavirus
Generic name
KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS
Approval order statement
APPROVAL FOR THE DIGENE HYBRID CAPTURE 2 (HC2) HIGH-RISK HPV DNA TEST. THE DEVICE IS INDICATED FOR: 1) TO SCREEN PATIENTS WITH ASCUS (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) PAP SMEAR RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY. 2) IN WOMEN 30 YEARS AND OLDER THE HC2 HIGH-RISK HPV DNA TEST CAN BE USED WITH PAP TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT.
Summary
<a href="http://www.accessdata.fda.gov/cdrh_docs/pdf/P890064S009B.pdf" target="_new">Summary of Safety and Effectiveness</a>

Current openFDA PMA Record#

Device
DIGENE HYBRID CAPTURE 2 (HC2) HIGH-RISK HPV DNA TEST
Applicant
Qiagen Gaithersburg, Inc.
PMA number
P890064
Supplement
S009
Product code
MAQ
Generic name
KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS
Decision date
2003-03-31
Decision code
APPR
Date received
2001-10-01
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
APPROVAL FOR THE DIGENE HYBRID CAPTURE 2 (HC2) HIGH-RISK HPV DNA TEST. THE DEVICE IS INDICATED FOR: 1) TO SCREEN PATIENTS WITH ASCUS (ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE) PAP SMEAR RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY. THE RESULTS OF THIS TEST ARE NOT INTENDED TO PREVENT WOMEN FROM PROCEEDING TO COLPOSCOPY. 2) IN WOMEN 30 YEARS AND OLDER THE HC2 HIGH-RISK HPV DNA TEST CAN BE USED WITH PAP TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPV TYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY, OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENT MANAGEMENT.